Antiplatelet therapies for the treatment of cardiovascular disease.
about
Deciphering of ADP-induced, phosphotyrosine-dependent signaling networks in human platelets by Src-homology 2 region (SH2)-profilingPlatelets in Pulmonary Immune Responses and Inflammatory Lung DiseasesThe Wonders of Phosphodiesterase-5 Inhibitors: A Majestic HistoryHypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic ReviewPolysaccharide nanosystems for future progress in cardiovascular pathologiesPlatelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapiesAntiplatelet activity, P2Y₁ and P2Y₁₂ inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'″-P¹ ,P⁴-dithio-P²,P³-chloromethylenetetraphosphateDiscovery of novel GPVI receptor antagonists by structure-based repurposingDrug target mining and analysis of the Chinese tree shrew for pharmacological testingThe kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy.Inhibitory effect of caffeic acid on ADP-induced thrombus formation and platelet activation involves mitogen-activated protein kinases.Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.Targeting integrin and integrin signaling in treating thrombosis.Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report.Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents.Specific Combination of Salvianolic Acids As Core Active Ingredients of Danhong Injection for Treatment of Arterial Thrombosis and Its Derived Dry Gangrene.Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation.Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor.Platelet secretion and hemostasis require syntaxin-binding protein STXBP5.Resolvin E1 regulates adenosine diphosphate activation of human platelets.Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome?Platelets: still a therapeutical target for haemostatic disorders.CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution.Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis.Humanizing thrombi in mice.Purification and characterization of BmooAi: a new toxin from Bothrops moojeni snake venom that inhibits platelet aggregation.Platelet Gi protein Gαi2 is an essential mediator of thrombo-inflammatory organ damage in mice.Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.Pentamethylquercetin (PMQ) reduces thrombus formation by inhibiting platelet functionIncreased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expressionNewer agents in antiplatelet therapy: a review.Single mutations of ketoreductase ChKRED20 enhance the bioreductive production of (1S)-2-chloro-1-(3, 4-difluorophenyl) ethanol.Aspirin plus ticlopidine prevented experimental endocarditis due to Enterococcus faecalis and Streptococcus gallolyticus.Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation.New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptorsProtein kinase C mediates platelet secretion and thrombus formation through protein kinase D2Correlation between Platelet Gelsolin and Platelet Activation Level in Acute Myocardial Infarction Rats and Intervention Effect of Effective Components of Chuanxiong Rhizome and Red Peony Root.Integrin αIIbβ3: from discovery to efficacious therapeutic target
P2860
Q24309320-55C15B38-78FD-4005-A139-877C6DC4518AQ26739670-05DEB789-8F1F-4B4B-8E96-2B7C392CD741Q26741387-3DAFE6B2-CCC5-4D44-8854-0A1DDFBACB7AQ26801156-648D498A-B86B-448A-9C6C-A1A64934FFB9Q27025494-BBF9092D-680B-4989-841C-11E00D80978FQ28068448-5A6EDFCA-7FCD-4126-8F39-04AAFCCDFCFBQ28537750-EDF5AE1E-D9D2-471C-A40B-CF9D69CE1135Q28540147-103CBF55-11B3-4C17-87B2-1CE3B2FF387FQ28541742-6FD4D0C1-F633-4C84-9F95-1B68304FE686Q30498119-75FAA0FA-0F7C-459E-BD67-AA3D7DCBBFA9Q30663919-6B915971-CDA0-41D7-BB29-2F31E9232DD8Q33397223-507C44AA-9C90-4E8E-97B1-8CAE8709841FQ33417854-FF2F088A-69A5-4041-8EE6-AB82A72C11FBQ33423255-1341D832-CC7A-49A8-B105-4AFCC4932E5AQ33789829-6B4B3178-2ED8-4509-A234-0415FEEBB0A2Q33790281-127B2583-A6DD-4DDB-8F4B-C5EF9FF013EAQ33863833-1DC03BF2-3EB9-4061-9910-9809A6A7A3BFQ34060673-230969C8-4A78-4F58-A196-0C60985401F2Q34191373-31931433-4DD9-49EC-804F-2177287A5463Q34311741-6A3F8AFE-ED4A-4000-8596-CF2839A66ED8Q34315513-C6AB810C-52CB-4EB7-8707-62FE2F0BD132Q34475551-F42AC1E9-8C1F-46DF-BA10-473EE096B629Q34486685-DEA4778D-023A-4FF9-BAF1-676946478C05Q34552473-F5450920-972A-4EF5-8709-D6D9AC34146CQ35098090-DB183301-4843-44FA-BB6A-F26766DA1D9AQ35102293-C16C331E-5B6C-4EF8-A307-C24FFA6F2AC5Q35109254-E3E6B666-9B12-4A5C-9968-B27D6CA11D67Q35196189-D08A292F-187F-41B6-9104-7081E737185BQ35644702-A247D13B-CE59-4C8F-82E1-56DEC04845B1Q35671956-ED22C0FB-5563-4D00-B571-623C005284B4Q35709614-FD60A8BB-E780-47A5-8EC1-A5F3371F25CDQ35823171-A72CF597-779F-4F94-88B6-717C23B24D65Q36085620-18FCAA70-35BF-410A-A918-8F82315D0358Q36188155-22277493-0D2A-4627-9DFE-7D2194FC3E1FQ36226465-D19D229A-F7D1-458C-93BC-3D4D66D4681FQ36252847-D1EF8056-C3B4-4507-8783-49B1E24F5E7CQ36359617-B0FBE93A-5317-4E22-ACFF-D7D4D267C7CCQ36638649-F142FA1C-9402-4EBC-B016-3FB4156038DBQ36711580-94FE00B2-3279-47FB-A902-8BF317C1F387Q37011736-0D314BA0-4D05-4C6A-AD11-95A89B6FDFEA
P2860
Antiplatelet therapies for the treatment of cardiovascular disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antiplatelet therapies for the treatment of cardiovascular disease.
@en
Antiplatelet therapies for the treatment of cardiovascular disease.
@nl
type
label
Antiplatelet therapies for the treatment of cardiovascular disease.
@en
Antiplatelet therapies for the treatment of cardiovascular disease.
@nl
prefLabel
Antiplatelet therapies for the treatment of cardiovascular disease.
@en
Antiplatelet therapies for the treatment of cardiovascular disease.
@nl
P356
P1476
Antiplatelet therapies for the treatment of cardiovascular disease.
@en
P2093
Alan D Michelson
P2888
P304
P356
10.1038/NRD2957
P577
2010-02-01T00:00:00Z